Released Nov 13, 2013, after the close
10-Q filed Nov 14, 2013, 45 days after period end · 0001019687-13-004331
Q3 2013 · 10-Q
Revenue$5.53M$5.53M −8.7% vs Q3 2012−0.1% vs Q2 2013
Net Income-$234.00K-$234.00K N/M vs Q3 2012N/M vs Q2 2013
EPS Diluted$0.00$0.00 — vs Q3 2012no prior Q2 2013 on file
Operating Income-$236,000N/M
Operating Cash Flowderived$723,000+82.1%
Free Cash Flowderived$549,000+119.6%
Margins · derived
Operating margin-4.3%−5.9 pt vs Q3 2012
Net margin-4.2%−5.1 pt vs Q3 2012
What the release said
The release
Same quarter
| Metric | Q3 2013 | Q3 2012 | Q3 2011 | Q3 2010 |
|---|---|---|---|---|
| Revenue | $5.53M | $6.05M | $5.87M | $6.51M |
| Net Income | -$234.00K | $54.00K | -$837.00K | $124.00K |
| EPS Diluted | $0.00 | $0.00 | -$0.01 | $0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR